Atrium Therapeutics, Inc. (RNA) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.05
↓-63% vs avg
5yr avg: 2.83
30Y Low1.3·High6.0
ROE
↑
-9.4%
↓+69% vs avg
5yr avg: -30.6%
30Y Low-39%·High-9%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RNA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Atrium Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $218M | $1.2B | $3.2B | $661M | $1.2B | $985M | $553M | — | — |
| Enterprise Value | $-48231065 | $968M | $3.0B | $486M | $828M | $676M | $232M | — | — |
| P/E Ratio → | -2.85 | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.71 | 66.30 | 297.77 | 69.12 | 125.49 | 105.59 | 81.46 | — | — |
| P/B Ratio | 1.05 | 5.96 | 2.28 | 1.32 | 2.00 | 2.58 | 1.81 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RNA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 52.00 | 278.22 | 50.79 | 89.74 | 72.49 | 34.23 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
RNA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Atrium Therapeutics, Inc. earns an operating margin of -412.6%. Operating margins have expanded from -2464.4% to -412.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -9.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 78.0% | 85.0% | -984.9% | -454.0% | 100.0% | -2125.9% |
| Operating Margin | -412.6% | -412.6% | -3477.4% | -2464.4% | -1939.6% | -1265.8% | -652.4% | -747.4% | -2769.9% |
| Net Profit Margin | -411.9% | -411.9% | -2957.7% | -2219.9% | -1886.3% | -1265.4% | -653.5% | -1066.6% | -3148.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.4% | -9.4% | -33.5% | -39.3% | -36.3% | -34.3% | -36.8% | — | — |
| ROA | -8.3% | -8.3% | -29.4% | -33.5% | -32.6% | -31.0% | -20.6% | -49.0% | -299.7% |
| ROIC | -10.0% | -10.0% | -37.0% | -61.6% | -83.6% | -303.2% | — | — | — |
| ROCE | -9.0% | -9.0% | -37.6% | -41.5% | -36.3% | -32.9% | -21.8% | -40.3% | — |
RNA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $270M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.28 | -0.15 | -0.35 | -0.57 | -0.81 | -1.05 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -39.75 | — |
| Interest Coverage | — | — | — | — | — | — | -211.22 | -2.35 | -14.62 |
Net cash position: cash ($270M) exceeds total debt ($4M)
RNA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Atrium Therapeutics, Inc.'s current ratio of 6.53x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.58x to 6.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.53 | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 |
| Quick Ratio | 6.53 | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 |
| Cash Ratio | 6.46 | 6.46 | 15.32 | 7.38 | 11.77 | 13.67 | 22.50 | 9.24 | 0.67 |
| Asset Turnover | — | 0.07 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.10 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 945.31 | 329.23 | 153.34 | 35.22 | 64.54 | — | — |
RNA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Atrium Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $17M | $112M | $73M | $52M | $41M | $22M | $38M | $21M |
Peer Comparison
Compare RNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RNAYou | $218M | -2.8 | — | — | 100.0% | -412.6% | -9.4% | -10.0% | — |
 SRPT | $2B | -2.2 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 MDWD | $152M | -6.6 | — | — | 19.2% | -149.1% | -63.9% | -49.5% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $2B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 BMRN | $11B | 30.9 | 16.4 | 14.8 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ALNY | $38B | 123.5 | 68.2 | 82.5 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARWR | $11B | -6323.8 | 90.0 | 69.3 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.9 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.4 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.6 | 14.4 | 18.8 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in RNA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in RNA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs RNA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationRNA vs SRPT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Sarepta Therapeutics, Inc..
Compare NowRNA — Frequently Asked Questions
Quick answers to the most common questions about buying RNA stock.
What is Atrium Therapeutics, Inc.'s P/E ratio?
Atrium Therapeutics, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
What is Atrium Therapeutics, Inc.'s ROE?
Atrium Therapeutics, Inc.'s return on equity (ROE) is -9.4%. The historical average is -31.6%.
Is RNA stock overvalued?
Based on historical data, Atrium Therapeutics, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Atrium Therapeutics, Inc.'s profit margins?
Atrium Therapeutics, Inc. has 100.0% gross margin and -412.6% operating margin.